Information

Information

  1. Dec. 05, 2018

    MHLW Approves New Indication for RISEDRONATE Tablets and DOBUTAMINE I.V. Infusion [190KB/ pages] NEW

  2. Nov. 21, 2018

    MHLW Approves New Indication for LEVOFOLINATE I.V. Infusion [181KB/ pages] NEW

  3. Nov. 14, 2018

    IR "Summary of Financial Results for the 1st Half of FY2018" NEW

    IR "Financial Results for the 1st Half of FY 2018" NEW

  4. Oct. 24, 2018

    Upsher-Smith Launches Generic Version of ONFI® (Clobazam), CIV In Tablet And Oral Suspension Dosage Forms [145KB/ pages]

  5. Sep. 21, 2018

    Sawai Pharmaceutical Receives Public Knowledge-Based Applications for Anti-Cancer Agent OXALIPLATIN I.V. Infusion Solution for Additional Indication [219KB/ pages]

  6. Sep. 05, 2018

    MHLW Approves New Indication for ARIPIPRAZOLE Tablets 3 mg / 6 mg / 12 mg / 24mg [SAWAI] and ARIPIPRAZOLE Oral Solution 3 mg / 6 mg / 12 mg Packet [SAWAI] [221KB/ pages]

  7. Sep. 03, 2018

    Upsher-Smith Launches Generic Version of Lomotil® (Diphenoxylate Hydrochloride and Atropine Sulfate) Tablets [145KB/ pages]

  8. Aug. 16, 2018

    Sawai Pharmaceutical Receives Approvals for Six Compounds with 13 Strengths of Generic Drugs [90KB/ pages]

  9. Aug. 14, 2018

    IR "Summary of Financial Results for the 1st Quarter of FY2018"

    IR "Financial Results for the 1st Quarter of FY2018"

  10. Aug. 08, 2018

    Upsher-Smith Launches Bexarotene Capsules [145KB/ pages]

  11. Jul. 17, 2018

    Upsher-Smith Launches Vigabatrin for Oral Solution Under the Brand Name Vigadrone™ [146KB/ pages]

  12. Jun. 20, 2018

    Announcement on Completion of Transfer of Manufacturing and Marketing Approval of Zomig® Tablets 2.5 mg and Zomig® RM Tablets 2.5 mg, Migraine Treatment [129KB/ pages]

  13. Jun. 14, 2018

    Sawai Pharmaceutical Launches 7 Compounds with 17 Strengths of Generic Drugs [211KB/ pages]

  14. Jun. 06, 2018

    MHLW approves New Indication for OSELTAMIVIR Capsules 75mg [SAWAI] / Dry Syrup 3% [SAWAI] [230KB/ pages]

  15. May. 25, 2018

    Sawai Pharmaceutical Submits Public Knowledge-Based Application for Anti-Cancer Agent OXALIPLATIN I.V. Infusion Solution for Additional Indication [217KB/ pages]

  16. May. 15, 2018

    IR "Medium-Term Business Plan (M1 TRUST 2021)"

    IR "Summary of Financial Results for FY 2017"

    IR "Financial Results for FY 2017"

    Announcement on Personnel Changes [147KB/ pages]

  17. May. 10, 2018

    UPSHER-SMITH LAUNCHES DOXAZOSIN TABLETS, USP [139KB/ pages]

  18. Apr. 04, 2018

    MHLW approves New Indication for OLANZAPINE formulation and New Administration for MEROPENEM formulation [312KB/ pages]

  19. Mar. 26, 2018

    Announcement on Organizational Changes and Personnel Changes [286KB/ pages]

  20. Mar. 20, 2018

    MHLW approves New Indication for PRAMIPEXOLE HYDROCHLORIDE Tablets 0.125mg “SAWAI” / 0.5mg “SAWAI” [287KB/ pages]

  21. Feb. 15, 2018

    Sawai Pharmaceutical receives approvals for 8 compounds with 19 strengths of generic drugs [188KB/ pages]

  22. Feb. 13, 2018

    IR "Summary of Financial Results for the 3rd Quarter of FY2017"

    IR "Financial Results for the 3rd Quarter of FY2017"

  23. Nov. 13, 2017

    Sawai Pharmaceutical Forms Strategic Alliance with Sumitomo Corp in the US Generics Market

    IR "Summary of Financial Results for the 1st Half of FY2017"

    IR "Financial Results for the 1st Half of FY 2017"

  24. Aug. 14, 2017

    IR "Summary of Financial Results for the 1st Quarter of FY2017"

    IR "Financial Results for the 1st Quarter of FY2017"

  25. Jun. 01, 2017

    Sawai Pharmaceutical Completes Acquisition of Upsher-Smith Laboratories’ Generics Business

  26. May. 15, 2017

    IR “Summary of Financial Results for FY2016”

    IR "Financial Results for FY2016"

  27. Apr. 20, 2017

    Japan’s Sawai Pharmaceutical to Acquire the Generics Business of U.S. Upsher-Smith Laboratories

  28. Feb. 10, 2017

    IR "Summary of Financial Results for the 3rd Quarter of FY2016"

    IR "Financial Results for the 3rd Quarter of FY2016"

  29. Nov. 10, 2016

    IR "Summary of Financial Results for the 1st Half of FY2016"

    IR "Financial Results for the 1st Half of FY2016"

  30. Aug. 08, 2016

    IR "Summary of Financial Results for the 1st Quarter of FY2016"

    IR "Financial Results for the 1st Quarter of FY2016"

    IR "Medium-Term Business Plan (Revised Version) (M1 TRUST 2018)"

Information
Back to Top